158577-01-6Relevant articles and documents
Synthesis and evaluation of novel 2-oxo-1,2-dihydro-3-quinolinecarboxamide derivatives as serotonin 5-HT4 receptor agonists
Suzuki,Ohuchi,Asanuma,Kaneko,Yokomori,Ito,Isobe,Muramatsu
, p. 2003 - 2008 (2000)
A series of N-azabicycloalkyl-1-alkyl-2-oxo-1,2-dihydro-3-quinolinecarboxamides were synthesized and tested for serotonin 5-HT4 receptor-stimulating effects in the regulation of electrically-evoked contraction in guinea pig muscle. Among them, N-azabicycloalkyl-1-isopropyl-2-oxo-1,2-dihydro-3-quinolinecarboxamide (8c, 9c, 10c, 11c, 12c) exhibited potent serotonin 5-HT4 receptor-stimulating activity. The most potent compound, N-(endo-8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1-isopropyl-2-oxo-1,2-dihydro-3 -quinolinecarboxamide (8c, ED50= 36.3 nM), was seven times as active as cisapride, while 8c had no affinity for 5-HT,1A, 5-HT1D, D2, muscarinic M2 or muscarinic M3 receptors even at 10 μM. Compound 8c stimulated digestive tract motility in conscious fed dogs (1.0 mg/kg p.o.).
Prokinetic agent for bowel preparation
-
Page/Page column 5, (2008/12/09)
The invention provides methods of bowel preparation before a diagnostic, surgical or therapeutic procedure, in particular, bowel preparation before a colonoscopy procedure, using a 5-HT4 receptor agonist as a prokinetic agent.
5-HT4 receptor agonist compounds
-
Page/Page column 21, (2008/06/13)
The invention provides novel quinolinone-carboxamide 5-HT4 receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.